AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04624152 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Soccer heading
Description: A standardized and reliable soccer heading protocol will be used to induce subconcussive impacts for the experiment. A triaxial accelerometer (Triax Technologies, Norwalk, CT) embedded in a head-band pocket and positioned back of the head to monitor linear and rotational head accelerations. A JUGS soccer machine (JUGS Sports, Tualatin, OR) will be used to simulate a soccer throw-in with a standardized ball speed of 25 mph across all groups. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practices and games. Participants will stand approximately 40ft away from the machine to perform the heading. Participants will perform a total of 10 headers at a rate of 1 header per minute and will be instructed to direct the ball back towards the JUGS machine. Previous uses of this soccer heading model have reported an average peak linear acceleration per header of 14.5 to 33.5 g.
Study NCT00775606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir 400 mg/ritonavir 100 mg
Description: Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
Study NCT00775606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
Study NCT02774486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQP-AK-102
Description: IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.
Study NCT01196429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT02572141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens
Description: mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
Study NCT02572141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens
Description: Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
Study NCT00679679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 750 mg BID for 4 months
Study NCT00679679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diet counseling and exercise
Study NCT05066828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: two pieces obturator
Description: patient received two pieces obturator connecting by magnet attachment
Study NCT05066828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: two pieces obturator
Description: patient received two pieces obturator connecting by magnet attachment
Study NCT02630082 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Circumcision
Study NCT02630082 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flexible sigmoidoscopy
Study NCT02704221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit activity tracker
Description: Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data
Study NCT02704221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit activity tracker
Description: Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data
Study NCT02704221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary rewards
Description: Set weekly step-count goals based on the previous week's performance and receive monetary rewards for meeting the goals. The schedule of rewards increases as step-count goals increase.
Study NCT02704221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPT training sessions
Description: Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
Study NCT02704221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BPT training sessions
Description: Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
Study NCT03179592 — intervention group
Intervention type: DRUG
Intervention: Ultravist 370Mg I/Ml Solution for Injection
Description: Reduced contrast-volume injection protocols based on patient specific tube voltage.
Study NCT00285974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
Description: metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
Study NCT00652431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vytorin + Niaspan
Description: Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
Study NCT00652431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vytorin
Description: Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
Study NCT00652431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niaspan
Description: Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
Study NCT02366663 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90-Yttrium Ibritumomab tiuxetan
Description: 0.4 mCi/kg given IV
Study NCT02366663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT02366663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carmustine
Description: Given IV
Study NCT02366663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02366663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT02366663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02366663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV
Study NCT02366663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT02366663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Given IV
Study NCT02366663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplant
Description: Autologous Hematopoietic Stem Cell Transplantation (ASCT)
Study NCT02366663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Hematopoietic Stem Cell Transplant
Description: Autologous Hematopoietic Stem Cell Transplantation (ASCT)
Study NCT02366663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03095352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Given IV
Study NCT03095352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
Study NCT04020380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 250Mg Capsule
Description: 250 mg OD
Study NCT04998903 — intervention group
Intervention type: PROCEDURE
Intervention: Fiberoptic Bronchoscopy
Description: Fiberoptic bronchoscopy done under conscious sedation
Study NCT01259856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGASYS
Description: The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
Study NCT01259856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
Study NCT01259856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
Study NCT01259856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
Study NCT02731391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor reconstruction（with or without mesh）
Study NCT02731391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor reconstruction（with or without mesh）
Study NCT02065310 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)
Description: Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 \& 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications.
Study NCT01860534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eye covers
Description: The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
Study NCT03095352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: For HER2+ patients: IV every 3 weeks using standard approved dosing
Study NCT04405505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT04405505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor.
Study NCT04405505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel for Injection (albumin bound)
Description: a anti-microtubule drug.
Study NCT02080689 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decipher
Study NCT01665755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upstroke Compression Defibrillation
Study NCT01665755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precompression Defibrillation
Study NCT00685620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reinforcement Based Treatment
Description: 3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment
Study NCT00685620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement Based Treatment
Description: 3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment
Study NCT01504854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
Study NCT01504854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
Study NCT02356406 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Celiac Plexus Radiosurgery
Description: 5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.~It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis.
Study NCT01510808 — intervention group
Intervention type: PROCEDURE
Intervention: orthodontic treatment
Description: Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
Study NCT02003560 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated partial breast irradiation
Description: 9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
Study NCT01702363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
Study NCT00946530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Participants uses bright light
Study NCT00946530 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants uses dim light
Study NCT03349541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex Care Curriculum
Description: A well-established approach to curriculum development was utilized to develop competency-based objectives aligned with the Canadian CanMEDS Physician Competency Framework, identify appropriate educational strategies and design relevant evaluations.
Study NCT00118482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fludrocortisone acetate
Description: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
Study NCT00118482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludrocortisone acetate
Description: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
Study NCT01152008 — intervention group
Intervention type: OTHER
Intervention: tourniquet ischemia
Description: Recording of cutaneous blood flow on the forearm at rest and during cycle exercise 50W before and following tourniquet ischemia
Study NCT03934892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum lactate
Description: check lactate levels during cardiopulmonary bypass in adult cardiac operations
Study NCT04072861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-9
Description: intravenous administration
Study NCT04204720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle (Chiba)
Description: intravascular injection using chiba needle during caudal epidural block
Study NCT04204720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: needle (Whitacre)
Description: intravascular injection using whitacre needle during caudal epidural block
Study NCT04611295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Teleneurological evaluation and support
Description: The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.
Study NCT01884636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral
Study NCT01884636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: oral
Study NCT03566186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Photobiomodulation or photobiostimulation, this technique is the application of monochromatic light that can influence cellular activity through inhibition or stimulation of chemical and biological functions.
Study NCT03566186 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same procedures as in the active phototherapy group was applied to the placebo group; however, the emitter was disabled. The device was emit the same sounds regardless of the programmed mode (active phototherapy).
Study NCT03566186 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Passive recovery
Description: Participants was remain sat for passive recovery supervised by an independent therapist during the period when the other groups are received recovery strategies.
Study NCT03043638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+ADM+PRP
Description: CAF+ADM+PRP group treated with coronally advanced flap technique including ADM placement, In CAF+ADM+PRP group, ADM was hydrated in the platelet-poor plasma (PPP) and the PRP was applied to surgical sites prior to final suturing.
Study NCT03043638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF+ADM
Description: CAF+ADM group treated with coronally advanced flap technique including ADM placement without PRP application
Study NCT01607372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2245035
Description: GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
Study NCT02125487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching using Hybrid Simulation of breast examination
Description: Students in the intervention/experimental group will receive the regular lecture given at the American University of Beirut and will attend a screening of an educational video on the technique of CBE, in addition to the hybrid simulation teaching activities in the simulation lab (standardized patient wearing breast examination simulator jackets)
Study NCT02125487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teaching using traditional method
Description: Students in the control group will receive the regular lecture given at the American University of Beirut and will attend the usual simulation lab teaching activities (single breast silicone model without any actors). The only new introduction to the curriculum is an educational video on the technique of CBE.
Study NCT03056495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-hydroxy-N'-phenyl-octanediamide (Vorinostat)
Description: N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
Study NCT01633996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
Study NCT00646971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP device
Description: for 4 weeks
Study NCT00646971 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo device
Description: for 4 weeks
Study NCT01607372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Type 1 amber glass bottle
Description: fitted with a metered Valios VP7 pump
Study NCT01607372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As for GSK2245035 nasal spray solution except for omission of the active ingredient
Study NCT04656886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion
Study NCT04656886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Infusion